[CH3:1][C:2]1([CH3:22])[C:10]2[N:9]=[C:8]([C:11]3[C:12]([CH3:21])=[CH:13][C:14]([CH3:20])=[C:15]([CH:19]=3)[C:16](O)=[O:17])[NH:7][C:6]=2[CH2:5][O:4][CH2:3]1.Cl.[NH:24]1[CH2:29][CH2:28][CH:27]([C:30]2[CH:37]=[CH:36][C:33]([C:34]#[N:35])=[CH:32][CH:31]=2)[CH2:26][CH2:25]1.CCN(C(C)C)C(C)C>CN(C=O)C.C(OCC)(=O)C>[CH3:1][C:2]1([CH3:22])[C:10]2[N:9]=[C:8]([C:11]3[C:12]([CH3:21])=[CH:13][C:14]([CH3:20])=[C:15]([CH:19]=3)[C:16]([N:24]3[CH2:29][CH2:28][CH:27]([C:30]4[CH:37]=[CH:36][C:33]([C:34]#[N:35])=[CH:32][CH:31]=4)[CH2:26][CH2:25]3)=[O:17])[NH:7][C:6]=2[CH2:5][O:4][CH2:3]1Crude 5-(7,7-Dimethyl-3,4,6,7-tetrahydropyrano[3,4-d]imidazol-2-yl)-2,4-dimethylbenzoic acid (compound 449.4, 0.086 mmol) was dissolved in DMF (1 mL). 4-(Piperidin-4-yl)benzonitrile hydrochloride (compound 1.5, 19 mg, 0.086 mmol), 2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate(V) (HBTU) (65 mg, 0.17 mmol) and DIEA (45 μl, 0.26 mmol) were added and the mixture was stiffed at room temperature for 16 hrs. The mixture was then diluted with ethyl acetate (10 mL) and washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (ethyl acetate) to obtain the title compound as a solid foam (15 mg, 30%). m/z (ES+) 469 (M+H)+.